Biovail Rx Products Spur Revenue Growth, Fuisz Acquisition Expands Pipeline
This article was originally published in The Tan Sheet
Executive Summary
While Biovail's branded and generic Rx products spurred second quarter and first half revenue and income growth, the $154 mil. acquisition of Fuisz Technologies and its drug delivery systems will give the Canadian pharmaceutical company an opening into the OTC, nutraceutical and food ingredient markets.